Apollon Formularies (STU:73R) EV-to-EBITDA : -2.63 (As of Jun. 01, 2024)

Apollon Formularies EV-to-EBITDA Chart

Apollon Formularies Annual Data
	Trend	Jun10	Jun11	Dec12	Dec13	Dec14	Dec17	Dec18	Dec19	Dec20	Dec21
EV-to-EBITDA		Get a 7-Day Free Trial					-	0.32	-4.63	-4.97	-7.73

Apollon Formularies Semi-Annual Data
	Jun11	Jun12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Jun23
EV-to-EBITDA	Get a 7-Day Free Trial											-4.97	-	-7.73	-	-

Competitive Comparison of Apollon Formularies's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollon Formularies's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's EV-to-EBITDA falls into.

Apollon Formularies EV-to-EBITDA Calculation

Apollon Formularies's EV-to-EBITDA for today is calculated as:

Apollon Formularies's current Enterprise Value is €1.24 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Apollon Formularies's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollon Formularies  (STU:73R) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Apollon Formularies's PE Ratio for today is calculated as:

Apollon Formularies's share price for today is €0.0005.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Apollon Formularies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.001.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Apollon Formularies EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollon Formularies (STU:73R) Business Description